Autumn Glory Partners LLC Raises Position in Pfizer Inc. (NYSE:PFE)

Autumn Glory Partners LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 29.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 39,159 shares of the biopharmaceutical company’s stock after acquiring an additional 8,909 shares during the period. Autumn Glory Partners LLC’s holdings in Pfizer were worth $1,045,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in PFE. Creative Planning increased its position in shares of Pfizer by 17.1% during the third quarter. Creative Planning now owns 1,820,731 shares of the biopharmaceutical company’s stock valued at $52,692,000 after acquiring an additional 266,167 shares in the last quarter. Swedbank AB increased its position in shares of Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after acquiring an additional 37,636 shares in the last quarter. Cornerstone Wealth Management LLC increased its position in shares of Pfizer by 8.1% during the third quarter. Cornerstone Wealth Management LLC now owns 77,912 shares of the biopharmaceutical company’s stock valued at $2,255,000 after acquiring an additional 5,854 shares in the last quarter. nVerses Capital LLC increased its position in shares of Pfizer by 154.1% during the third quarter. nVerses Capital LLC now owns 15,500 shares of the biopharmaceutical company’s stock valued at $449,000 after acquiring an additional 9,400 shares in the last quarter. Finally, Good Life Advisors LLC increased its position in shares of Pfizer by 7.4% during the third quarter. Good Life Advisors LLC now owns 56,199 shares of the biopharmaceutical company’s stock valued at $1,626,000 after acquiring an additional 3,869 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by company insiders.

Pfizer Trading Down 0.6 %

NYSE:PFE opened at $25.50 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $144.48 billion, a price-to-earnings ratio of 18.08, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The business has a fifty day moving average price of $26.28 and a 200-day moving average price of $27.62.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 EPS. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.75%. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is presently 121.99%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on PFE shares. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Wolfe Research began coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.